A 2026 narrative review by Tommasino et al. in Journal of Cosmetic Dermatology found spironolactone, metformin, and bicalutamide show subgroup or adjunctive promise for moderate-to-severe acne beyond isotretinoin but lack head-to-head comparisons with isotretinoin. For teens with inflammatory acne — red, tender pimples plus deeper painful lumps — it creates no new teen-specific efficacy estimates because it summarizes prior studies.
Inflammatory acne responds best when treatment matches its driver. Hormones, insulin resistance, and conditions like polycystic ovary syndrome can sustain breakouts in teen girls. That match matters more than the drug name alone.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What the 2026 review did
- Where does spironolactone help most?
- Is metformin an acne drug?
- Why is bicalutamide handled differently?
- What should teens and parents check first?
What the 2026 review did
The review was a narrative literature review, not a new randomized trial. According to PubMed, it surveyed systemic options beyond isotretinoin, including repurposed hormonal and metabolic drugs the PubMed record.
That design can map where each drug has been studied. It cannot set a dose, success rate, or ranking for teens with inflammatory acne.
Where does spironolactone help most?
Spironolactone blocks androgen effects that drive oil production and clogged pores. Adult women are its best-studied acne group, with benefit reported at 50–200 mg daily in retrospective cohorts. Support comes from those cohorts plus a 2025 placebo-controlled meta-analysis that found improvement without a substantial rise in adverse events, described in the 2025 Journal of Cosmetic Dermatology meta-analysis.
That evidence supports conditional use based on severity, tolerance, and preference. Spironolactone is not FDA-approved for acne and is used off-label. Authors link that gap to limited published data, while UK and Irish clinicians cite hormonal effects in prepubertal girls and pregnancy and teratogenicity risk for patients age 18 or younger.
Is metformin an acne drug?
Metformin lowers IGF-1 and androgen signaling and helps acne mainly with polycystic ovary syndrome or insulin resistance. A meta-analysis of four adolescent PCOS trials with 170 patients found oral contraceptives modestly better for acne and cycle control, while metformin helped BMI and metabolic measures. An assessor-blinded add-on trial found metformin and doxycycline produced similar Investigator Global Assessment reductions.
Wiley trial summaries present that result as support for adjunctive use, not first-line monotherapy for non-PCOS inflammatory acne. Teens with irregular periods, excess hair growth, scalp oiliness, or rapid weight gain deserve metabolic review. Clear skin without cycle and metabolic improvement still leaves the driver untreated.
Why is bicalutamide handled differently?
Bicalutamide is a potent androgen blocker with a narrow approved use. According to the FDA, it is approved only as 50 mg daily with an LHRH analog for advanced prostate cancer, with labeling history contraindicating use in women and children and warnings for liver injury the FDA Casodex label. Dermatology use at 25–50 mg for hyperandrogenic acne, seborrhea, and hair loss is off-label.
It rests on small case series and hair-loss cohorts, with elevated liver enzymes in about 2–10% and a 2024 adolescent case of toxicity that resolved after stopping the drug. Liver monitoring is central to that risk. A teen should never start it for ordinary inflammatory acne without specialist review of hormones, liver tests, and pregnancy risk.
What should teens and parents check first?
Severe acne in females under 18 with PCOS predicted systemic therapy in a 2026 retrospective. The same Pediatric Dermatology study found Hispanic patients received less spironolactone, contraceptives, and isotretinoin, pointing to access barriers that families should name early.
Use the dermatology visit to close those gaps: Bring cycle dates, current prescriptions, supplements, and prior acne treatments. Ask what change would trigger a switch in plan within eight to twelve weeks.
- review cycle pattern, hair loss, excess hair, acne location, and insulin-resistance signs
- review pregnancy risk, potassium risk on spironolactone, and liver risk on bicalutamide
- ask whether acne is severe, hormonal, PCOS-linked, or treatment-resistant, and what follow-up labs are planned
You Might Also Like
- Limited Topical Spironolactone Evidence in the 2026 Review: Study Design and Evidence Limits for Teens With Inflammatory Acne
- Adult Female Acne Antiandrogen Treatments in a 2026 Review: Study Design and Evidence Limits for Teens With Inflammatory Acne
- Topical Clascoterone Evidence Revisited in 2026: Study Design and Evidence Limits for Teens With Inflammatory Acne